{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:43:57Z","timestamp":1785336237717,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013165","name":"Otto A. Malm Lahjoitusrahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010129","name":"Maud Kuistilan Muistos\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015984","name":"PerkinElmer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015984","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>To evaluate the performance of first trimester maternal serum glycosylated (<jats:italic>Sambucus nigra<\/jats:italic> lectin-reactive) fibronectin in prediction of gestational diabetes mellitus (GDM).\n<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this case\u2013control study, first trimester maternal serum glycosylated fibronectin and fibronectin were measured in 19 women who consequently developed GDM and in 59 control women with normal pregnancy outcomes. Adiponectin was used as a reference protein to evaluate relation of glycoprotein to SNA-lectin-reactive assay format. Samples were taken during gestational weeks 9<jats:sup>+6<\/jats:sup>\u201311<jats:sup>+6<\/jats:sup>. Data concerning GDM was obtained from the National Institute for Health and Welfare, which records the pregnancy outcomes of all women in Finland.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was no difference in maternal serum glycosylated fibronectin concentrations between women with consequent GDM [447.5\u00a0\u03bcg\/mL, interquartile range (IQR) 254.4\u2013540.9\u00a0\u03bcg\/mL] and control women (437.6\u00a0\u03bcg\/mL, IQR 357.1\u2013569.1\u00a0\u03bcg\/mL). Maternal serum fibronectin levels were significantly lower in GDM group (224.2\u00a0\u03bcg\/mL, IQR 156.8\u2013270.6\u00a0\u03bcg\/mL), compared to the control group (264.8\u00a0\u03bcg\/mL, IQR 224.6\u2013330.6\u00a0\u03bcg\/mL, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). There was no difference in assay formats for adiponectin.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>There was no association between first trimester maternal serum glycosylated (SNA-reactive) fibronectin and GDM.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00404-020-05670-8","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T11:02:21Z","timestamp":1594465341000},"page":"853-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Glycosylated fibronectin as a first trimester marker for gestational diabetes"],"prefix":"10.1007","volume":"302","author":[{"given":"Julia","family":"Alanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Appelblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teemu","family":"Korpimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Kouru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Sairanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Gissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Ryynanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-9676","authenticated-orcid":false,"given":"Jaana","family":"Nevalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"5670_CR1","volume-title":"Statistical Report 24\/2013","author":"National Institute for Health and Welfare. Perinatal statistics: parturients, deliveries and newborns","year":"2012","unstructured":"National Institute for Health and Welfare. Perinatal statistics: parturients, deliveries and newborns (2012) Statistical Report 24\/2013. National Institute for Health and Welfare, Helsinki"},{"key":"5670_CR2","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(09)60731-5","volume":"373","author":"L Bellamy","year":"2009","unstructured":"Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373:1773\u20131779. https:\/\/doi.org\/10.1016\/S0140-6736(09)60731-5","journal-title":"Lancet"},{"key":"5670_CR3","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.ijgo.2008.11.025","volume":"104","author":"P Damm","year":"2009","unstructured":"Damm P (2009) Future risk of diabetes in mother and child after gestational diabetes mellitus. Int J Gynaecol Obstet 104:S25\u2013S26. https:\/\/doi.org\/10.1016\/j.ijgo.2008.11.025","journal-title":"Int J Gynaecol Obstet"},{"issue":"14","key":"5670_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2393-14-70","volume":"14","author":"K Rono","year":"2014","unstructured":"Rono K, Stach-Lempinen B, Klemetti MM, Kaaja RJ, Poyhonen-Alho M, Eriksson JG, Koivusalo SB, Andersson S, Huvinen E, RADIEL group (2014) Prevention of gestational diabetes through lifestyle intervention: study design and methods of a Finnish randomized controlled multicenter trial (RADIEL). BMC Pregnancy Childbirth 14(14):70. https:\/\/doi.org\/10.1186\/1471-2393-14-70","journal-title":"BMC Pregnancy Childbirth"},{"key":"5670_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s00125-009-1282-2","volume":"52","author":"A Kotronen","year":"2009","unstructured":"Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen MR, Taskinen MO, Yki-Jarvinen H (2009) Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52:684\u2013690. https:\/\/doi.org\/10.1007\/s00125-009-1282-2","journal-title":"Diabetologia"},{"key":"5670_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/AOG.0b013e3182a0c88b","volume":"122","author":"JP Rasanen","year":"2013","unstructured":"Rasanen JP, Snyder CK, Rao PV, Mihalache R, Heinonen S, Gravett MG, Roberts C, Nagalla S (2013) Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes. Obstet Gynecol 122:586\u2013594. https:\/\/doi.org\/10.1097\/AOG.0b013e3182a0c88b","journal-title":"Obstet Gynecol"},{"key":"5670_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.metabol.2015.07.015","volume":"64","author":"A Syngelaki","year":"2015","unstructured":"Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH (2015) First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. Metabolism 64:1485\u20131489. https:\/\/doi.org\/10.1016\/j.metabol.2015.07.015","journal-title":"Metabolism"},{"key":"5670_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00125-015-3855-6","volume":"59","author":"S Iliodromiti","year":"2016","unstructured":"Iliodromiti S, Sassarini J, Kelsey TW, Lindsay RS, Sattar N, Nelson SM (2016) Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia 59:692\u2013699. https:\/\/doi.org\/10.1007\/s00125-015-3855-6","journal-title":"Diabetologia"},{"key":"5670_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.5603\/GP.2016.0060","volume":"87","author":"M Migda","year":"2016","unstructured":"Migda M, Migda MS, Migda B, Krzy\u017canowska P, Wender-O\u017cegowska E (2016) Components of metabolic syndrome in the first trimester of pregnancy as predictors of adverse perinatal outcome. Ginekol Pol 87:644\u2013650. https:\/\/doi.org\/10.5603\/GP.2016.0060","journal-title":"Ginekol Pol"},{"key":"5670_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1900\/RDS.2016.13.236","volume":"13","author":"J Nevalainen","year":"2016","unstructured":"Nevalainen J, Sairanen M, Appelblom H, Gissler M, Timonen S, Ryyn\u00e4nen M (2016) First-trimester maternal serum amino acids and acylcarnitines are significant predictors of gestational diabetes. Rev Diabet Stud 13:236\u2013245. https:\/\/doi.org\/10.1900\/RDS.2016.13.236","journal-title":"Rev Diabet Stud"},{"key":"5670_CR11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2337\/db15-0966","volume":"65","author":"C Salomon","year":"2016","unstructured":"Salomon C, Scholz-Romero K, Sarker S, Sweeney E, Kobayashi M, Correa P, Longo S, Duncombe G, Mitchell MD, Rice GE, Illanes SE (2016) Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. Diabetes 65:598\u2013609. https:\/\/doi.org\/10.2337\/db15-0966","journal-title":"Diabetes"},{"key":"5670_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.metabol.2015.10.029","volume":"65","author":"A Syngelaki","year":"2016","unstructured":"Syngelaki A, Visser GH, Krithinakis K, Wright A, Nicolaides KH (2016) First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. Metabolism 65:131\u2013137. https:\/\/doi.org\/10.1016\/j.metabol.2015.10.029","journal-title":"Metabolism"},{"key":"5670_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/2230-8210.140226","volume":"19","author":"SR Nagalla","year":"2015","unstructured":"Nagalla SR, Snyder CK, Michaels JE, Laughlin MJ, Roberts CT, Balaji M, Balaji M, Seshiah V, Rao PV (2015) Maternal serum biomarkers for risk assessment in gestational diabetes. A potential universal screening test to predict GDM status. Indian J Endocrinol Metab 19:155\u2013159. https:\/\/doi.org\/10.4103\/2230-8210.140226","journal-title":"Indian J Endocrinol Metab"},{"key":"5670_CR14","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI112752","volume":"78","author":"JH Peters","year":"1986","unstructured":"Peters JH, Ginsberg MH, Bohl BP, Sklar LA, Cochrane CG (1986) Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest 78:1596\u20131603","journal-title":"J Clin Invest"},{"key":"5670_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.bi.57.070188.002111","volume":"57","author":"E Ruoslahti","year":"1988","unstructured":"Ruoslahti E (1988) Fibronectin and its receptors. Annu Rev Biochem 57:375\u2013413","journal-title":"Annu Rev Biochem"},{"key":"5670_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/01.ATV.18.9.1363","volume":"18","author":"MK Magnusson","year":"1998","unstructured":"Magnusson MK, Mosher DF (1998) Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 18:1363\u20131370","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5670_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1164\/ajrccm\/138.1.167","volume":"138","author":"JH Peters","year":"1988","unstructured":"Peters JH, Ginsberg MH, Case CM, Cochrane CG (1988) Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis 138:167\u2013174","journal-title":"Am Rev Respir Dis"},{"key":"5670_CR18","first-page":"586","volume":"113","author":"JH Peters","year":"1989","unstructured":"Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH (1989) Elevated plasma levels of ED1+ (\u201ccellular\u201d) fibronectin in patients with vascular injury. J Lab Clin Med 113:586\u2013597","journal-title":"J Lab Clin Med"},{"key":"5670_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/0002-9378(90)90385-K","volume":"162","author":"CJ Lockwood","year":"1990","unstructured":"Lockwood CJ, Peters JH (1990) Increased plasma levels of ED1+ cellular fibronectin precede the clinical signs of preeclampsia. Am J Obstet Gynecol 162:358\u2013362","journal-title":"Am J Obstet Gynecol"},{"key":"5670_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/0002-9378(86)90748-9","volume":"154","author":"J Lazarchick","year":"1986","unstructured":"Lazarchick J, Stubbs TM, Romein L, Van Dorsten JP, Loadholt CB (1986) Predictive value of fibronectin levels in normotensive gravid women destined to become preeclamptic. Am J Obstet Gynecol 154:1050\u20131052. https:\/\/doi.org\/10.1016\/0002-9378(86)90748-9","journal-title":"Am J Obstet Gynecol"},{"key":"5670_CR21","doi-asserted-by":"publisher","first-page":"82.e1","DOI":"10.1016\/j.ajog.2014.07.052","volume":"212","author":"J Rasanen","year":"2015","unstructured":"Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT Jr, Nagalla SR, Gravett MG (2015) Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 212:82.e1\u20139. https:\/\/doi.org\/10.1016\/j.ajog.2014.07.052","journal-title":"Am J Obstet Gynecol"},{"key":"5670_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000486853","volume":"45","author":"AN Sweeting","year":"2019","unstructured":"Sweeting AN, Wong J, Appelblom H, Ross GP, Kouru H, Williams PF, Sairanen M, Hyett JA (2019) A novel early pregnancy risk prediction model for gestational diabetes mellitus. Fetal Diagn Ther 45:76\u201384. https:\/\/doi.org\/10.1159\/000486853","journal-title":"Fetal Diagn Ther"},{"key":"5670_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1464-5491.2011.03541.x","volume":"29","author":"BS Buckley","year":"2012","unstructured":"Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, Dunne VF, Teramo K (2012) Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening: a review. Diabet Med 29:844\u2013854. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03541.x","journal-title":"Diabet Med"},{"issue":"14","key":"5670_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1471-2393-14-185","volume":"31","author":"M Lindqvist","year":"2014","unstructured":"Lindqvist M, Persson M, Lindkvist M, Mogren I (2014) No consensus on gestational diabetes mellitus screening regimes in Sweden: pregnancy outcomes in relation to different screening regimes 2011 to 2012, a cross-sectional study. BMC Pregnancy Childbirth 31(14):185. https:\/\/doi.org\/10.1186\/1471-2393-14-185","journal-title":"BMC Pregnancy Childbirth"},{"key":"5670_CR25","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa042973","volume":"352","author":"CA Crowther","year":"2005","unstructured":"Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352:2477\u20132486. https:\/\/doi.org\/10.1056\/NEJMoa042973","journal-title":"N Engl J Med"},{"key":"5670_CR26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1056\/NEJMoa0902430","volume":"361","author":"MB Landon","year":"2009","unstructured":"Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM, Sciscione A, Catalano P (2009) A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 361:1339\u20131348. https:\/\/doi.org\/10.1056\/NEJMoa0902430","journal-title":"N Engl J Med"},{"issue":"361","key":"5670_CR27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMe0907617","volume":"1","author":"DA Sacks","year":"2009","unstructured":"Sacks DA (2009) Gestational diabetes\u2013whom do we treat? N Engl J Med 1(361):1396\u20131398. https:\/\/doi.org\/10.1056\/NEJMe0907617","journal-title":"N Engl J Med"},{"key":"5670_CR28","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0707943","volume":"358","author":"The HAPO Study Cooperative Research Group","year":"2008","unstructured":"The HAPO Study Cooperative Research Group (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991\u20132002. https:\/\/doi.org\/10.1056\/NEJMoa0707943","journal-title":"N Engl J Med"},{"key":"5670_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012115","author":"EA Huhn","year":"2016","unstructured":"Huhn EA, Fischer T, G\u00f6bl CS, Todesco Bernasconi M, Kreft M, Kunze M, Schoetzau A, Dolzlmuller E, Eppel W, Husslein P, Ochsenbein-Koelble N, Zimmermann R, Baz E, Prompeler H, Bruder E, Hahn S, Hoesli I (2016) Screening of gestational diabetes mellitus in early pregnancy by oral glucose tolerance test and glycosylated fibronectin: study protocol for an international, prospective, multicentre cohort trial. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2016-012115","journal-title":"BMJ Open"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05670-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:20:53Z","timestamp":1625959253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05670-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5670"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05670-8","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"3 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Heidi Appelblom, MSc, is a research scientist, Teemu Korpimaki, PhD, is a senior chemist, Heikki Kouru, PhD, is a senior statistician and Mikko Sairanen, PhD, is a scientific liaison working for PerkinElmer, Turku, Finland. PerkinElmer is a supplier of biochemical products for early pregnancy trisomy screening performed in Oulu University Hospital. The other authors have no potential conflicts of interest to disclose. The authors alone are responsible for the content and writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Ethics Committee of Oulu University Hospital and the National Institute for Health and Welfare approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived by the IRB as this was a retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}